Skip to main content

Published locations for Liraglutide cut risk of microvascular renal complications by 22% in type 2 diabetes; no eye benefit

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Liraglutide cut risk of microvascular renal complications by 22% in type 2 diabetes; no eye benefit

User login

  • Reset your password
  • /content/liraglutide-cut-risk-microvascular-renal-complications-22-type-2-diabetes-no-eye-benefit
  • /familypracticenews/article/113755/diabetes/liraglutide-cut-risk-microvascular-renal-complications-22
  • /internalmedicinenews/article/113755/diabetes/liraglutide-cut-risk-microvascular-renal-complications
  • /vascularspecialistonline/article/113755/diabetes/liraglutide-cut-risk-microvascular-renal
  • /clinicalendocrinologynews/article/113755/diabetes/liraglutide-cut-risk-microvascular-renal
  • /endocrinology/article/113755/diabetes/liraglutide-cut-risk-microvascular-renal-complications-22-type
  • /internalmedicine/article/113755/diabetes/liraglutide-cut-risk-microvascular-renal-complications-22
  • /familymedicine/article/113755/diabetes/liraglutide-cut-risk-microvascular-renal-complications-22
  • /type-2-diabetes-icymi/article/113755/diabetes/liraglutide-cut-risk-microvascular-renal-complications